Program
pembrolizumab, berahyaluronidase alfa drug combination
Also written as “Pembrolizumab (+) Berahyaluronidase alfa” and “Pembrolizumab Formulated with Berahyaluronidase Alfa”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Hematologic Neoplasms · Carcinoma, Squamous Cell, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 87 open or running | phase 3since Mar 29, 2018 | Mar 29, 2018 | Mar 31, 2028phase 2 · NCT06041802 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 29, 2018First study: phase 3 study in Hematologic NeoplasmsFirst studyNCT03486873 · 3,500 planned · United States, Argentina, Australia and more
- Aug 18, 2021Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05017012 · 142 enrolled · Chile, Hungary, Japan and more
- Jan 27, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05722015 · 377 enrolled · United States, Argentina, Brazil and more
- Sep 11, 2023Phase 2 study in Carcinoma, Squamous CellNCT06041802 · 19 enrolled · Japan
- Oct 19, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06099782 · 147 enrolled · United States, Argentina, Australia and more
- Jan 9, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06212752 · 39 enrolled · Japan
- Jul 11, 2024Phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT06504394 · 66 enrolled · United States, Australia, Chile and more
- Nov 18, 2024Phase 3 study in Lung NeoplasmsNCT06698042 · 67 enrolled · United States, China, Germany and more
Ahead
- Mar 31, 2028Primary completion: phase 2 study in Carcinoma, Squamous CellNCT06041802
- Nov 8, 2028Primary completion: phase 2 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT06504394
- Aug 4, 2043Primary completion: phase 3 study in Hematologic NeoplasmsNCT03486873
TargetBeta
“A fixed-dose co-formulation composed of pembrolizumab, a humanized immunoglobulin G4 (IgG4) monoclonal antibody directed against human cell surface receptor PD-1 (programmed death-1; programmed cell death-1; cluster of differentiation 279; CD279), and berahyaluronidase alfa, a recombinant variant of”NCIt, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06698042Lung Neoplasms · United States, China, Germany and more | 3 | Active, not recruiting | Mar 12, 2026 | 67 |
| NCT06504394Parkinson Disease 4, Autosomal Dominant Lewy Body · United States, Australia, Chile and more | 2 | Active, not recruiting | Nov 8, 2028 | 66 |
| NCT06212752Carcinoma, Non-Small-Cell Lung · Japan | 3 | Active, not recruiting | Nov 6, 2024 | 39 |
| NCT06099782Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 2 | Active, not recruiting | Apr 9, 2025 | 147 |
| NCT06041802Carcinoma, Squamous Cell · Japan | 2 | Active, not recruiting | Mar 31, 2028 | 19 |
| NCT05722015Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Jul 12, 2024 | 377 |
| NCT05017012Parkinson Disease 4, Autosomal Dominant Lewy Body · Chile, Hungary, Japan and more | 1 | Completed | May 19, 2026 | 142 |
| NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Aug 4, 2043 | 3,500 |
How it is read
Names in the registry
- “Pembrolizumab (+) Berahyaluronidase alfa”, 6 entries
- “Pembrolizumab Formulated with Berahyaluronidase Alfa”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Hematologic Neoplasms, 1 study
- Carcinoma, Squamous Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.